Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections
Kevin J Selva,Pradhipa Ramanathan,Ebene R Haycroft,Arnold Reynaldi,Deborah Cromer,Chee Wah Tan,Lin-Fa Wang,Bruce D Wines,P Mark Hogarth,Laura E Downie,Samantha K Davis,Ruth A Purcell,Helen E Kent,Jennifer A Juno,Adam K Wheatley,Miles P Davenport,Stephen J Kent,Amy W Chung,Kevin J. Selva,Ebene R. Haycroft,Bruce D. Wines,P. Mark Hogarth,Laura E. Downie,Samantha K. Davis,Ruth A. Purcell,Helen E. Kent,Jennifer A. Juno,Adam K. Wheatley,Miles P. Davenport,Stephen J. Kent,Amy W. Chung
DOI: https://doi.org/10.1172/jci.insight.172470
IF: 9.4958
2023-09-23
JCI Insight
Abstract:Understanding mucosal antibody responses from SARS-CoV-2 infection and/or vaccination is crucial to develop strategies for longer term immunity, especially against emerging viral variants. We profiled serial paired mucosal and plasma antibodies from COVID-19 vaccinated only vaccinees (vaccinated, uninfected), COVID-19–recovered vaccinees (recovered, vaccinated), and individuals with breakthrough Delta or Omicron BA.2 infections (vaccinated, infected). Saliva from COVID-19–recovered vaccinees displayed improved antibody-neutralizing activity, Fcγ receptor (FcγR) engagement, and IgA levels compared with COVID-19–uninfected vaccinees. Furthermore, repeated mRNA vaccination boosted SARS-CoV-2–specific IgG2 and IgG4 responses in both mucosa biofluids (saliva and tears) and plasma; however, these rises only negatively correlated with FcγR engagement in plasma. IgG and FcγR engagement, but not IgA, responses to breakthrough COVID-19 variants were dampened and narrowed by increased preexisting vaccine-induced immunity against the ancestral strain. Salivary antibodies delayed initiation following breakthrough COVID-19 infection, especially Omicron BA.2, but rose rapidly thereafter. Importantly, salivary antibody FcγR engagements were enhanced following breakthrough infections. Our data highlight how preexisting immunity shapes mucosal SARS-CoV-2–specific antibody responses and has implications for long-term protection from COVID-19.
medicine, research & experimental